Chronic News and Research

RSS

ULURU present Altrazeal at 2010 WOCN/WCET joint conference

ULURU Inc. announced today that six posters detailing clinical experience using Altrazeal™ Transforming Powder Dressing will be presented at the 2010 Joint Conference of the Wound Ostomy and Continence Nurses Society (WOCN) and World Council of Enterostomal Therapists (WCET) on June 14-16 in Phoenix, Arizona.

15 Jun 2010

VA Federal Supply Schedule Service approves CTT as vendor for Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Department of Veterans Affairs' Federal Supply Schedule Service has accepted CTT's application to be an approved vendor for its Calmare® Pain Therapy Treatment. This decision will enable CTT to sell Calmare Pain Therapy to physicians throughout the Federal government, with the expectation of significant sales in that market sector, which includes the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, the Bureau of Prisons, and State Veteran Homes.

15 Jun 2010

CLC-5 protein plays active part in inherited kidney disorder: Scientists

Scientists from the University of Leeds have discovered the mechanisms of a protein known to play an active part in the inherited kidney disorder, Dent's disease. The findings provide a new focus for future therapies for the disease, for which there is currently no cure.

15 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

Healthcore Media launches dynamic, educational and community-oriented health website

Healthcore Media, LLC has launched http://www.onehealth.com, a dynamic, educational and community-oriented health website that is quickly taking center stage among health portals. Chronic illnesses are at an all-time high, and unbiased medical information and supportive connections with others are taking top priority across the world. One Health has answered the call.

14 Jun 2010

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions.

14 Jun 2010

Human Genome Sciences receives FDA feedback for ZALBIN BLA

Human Genome Sciences, Inc. today announced that it has received preliminary written feedback from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) seeking approval in the United States to market 900-mcg ZALBIN™ (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C. FDA has expressed concerns regarding the risk benefit assessment of ZALBIN dosed at 900-mcg every two weeks.

14 Jun 2010

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Monoclonal antibodies are the largest class of biotherapeutic drugs. When administered to infected organisms to blunt the propagation of pathogenic viruses, they may also induce a long-lasting and protective antiviral immune response similar to that achieved by vaccination. These results obtained in mice by the "Oncogenèse et Immunothérapie" group at the Institut de Génétique Moléculaire de Montpellier (CNRS/Universités Montpellier 1 and 2), have been published on 10 June in PLoS Pathogens.

14 Jun 2010

Evidence-based review of TBI in sport

Experts from Johns Hopkins Medicine hosted a press conference following a continuing medical education program on the epidemiology of head injury in professional football. The program was an evidence-based review of traumatic brain injury in the sport.

14 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

National MS Society commits over $2.4M to support 7 CCSVI research projects

Over $2.4 million has been committed by the National MS Society (USA) and the MS Society of Canada to support 7 new research projects focusing on the role of CCSVI in MS.

14 Jun 2010

U.S. healthcare industry can eliminate $3.6 trillion in healthcare waste over next 10 years: White paper

The U.S. healthcare industry can eliminate $3.6 trillion in healthcare waste over the next 10 years by addressing a series of operational inefficiencies, according to a white paper published today by Thomson Reuters.

14 Jun 2010

Homeless Brisbane population at risk of dying early: survey

A recent survey has shown that more than 50 percent of Brisbane’s homeless community is at a higher risk of early deaths. The survey was conducted by interviewing at least 231 people who live on Brisbane's streets, using an index to determine their risk of dying or mortality risk.

14 Jun 2010

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer (http://www.mayoclinic.org/kidney-cancer/research.html) surgery leads to a greater risk for patients developing chronic kidney disease, a Mayo Clinic and Cleveland Clinic collaborative research team has found. The study was published today in the journal, European Urology.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

TWI launches new educational module to understand role of biofilms in chronic wound infections

The Wound Institute today announced the launch of a new educational module "Exploring Biofilms," an accredited, online course designed to help practicing wound care specialists better understand the role that biofilms play in chronic wound infections.

14 Jun 2010

3M Health Care launches new foam adhesive dressings for acute and chronic wounds

3M Health Care today announced the introduction of a full line of new, innovative Tegaderm™ High Performance Foam Adhesive Dressings. In clinical and laboratory tests, these new adhesive foam wound dressings outperform other leading foam adhesive dressings in managing the full range of low- to high-moisture conditions that can be present in chronic and acute wounds.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

Trauma patients without insurance more likely to die of injuries than privately insured patients: Study

Trauma patients without insurance are more likely to die of their injuries from auto accidents and gunshot wounds than privately insured patients with similar injuries, according to findings of an analysis of 193,804 patients from 649 facilities conducted by University Buffalo emergency medicine physicians.

14 Jun 2010

Chronic News and Research

ULURU present Altrazeal at 2010 WOCN/WCET joint conference

VA Federal Supply Schedule Service approves CTT as vendor for Calmare Pain Therapy Treatment

CLC-5 protein plays active part in inherited kidney disorder: Scientists

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Healthcore Media launches dynamic, educational and community-oriented health website

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Human Genome Sciences receives FDA feedback for ZALBIN BLA

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Evidence-based review of TBI in sport

ARBs increase risk of cancer: Study

National MS Society commits over $2.4M to support 7 CCSVI research projects

U.S. healthcare industry can eliminate $3.6 trillion in healthcare waste over next 10 years: White paper

Homeless Brisbane population at risk of dying early: survey

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

Olfactory function tests could help in treating patient in early stages of PD

TWI launches new educational module to understand role of biofilms in chronic wound infections

3M Health Care launches new foam adhesive dressings for acute and chronic wounds

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

Chiasma successfully completes Phase I clinical study of Octreolin

Trauma patients without insurance more likely to die of injuries than privately insured patients: Study

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News